Basic and Meal Stimulated Plasma GIP Levels are Higher in Lean PCOS Women with FAI over 5

 

 Buy Article Permissions and Reprints

Abstract

Objective: Glucose dependent insulinotropic peptide (GIP) belongs to the incretins which are responsible for 70% of the insulin release after oral glucose intake. Its impaired secretion was noted in several conditions involving insulin resistance, including polycystic ovary syndrome (PCOS), known as the state with increased testosterone level. This paper considers a possible relationship between the free androgen index (FAI) and basal as well as meal stimulated level of GIP in lean women affected by PCOS. To our knowledge, no previous study has evaluated the matter so far.

Design: cross-sectional study

Methods: 50 age-matched lean women (BMI=20.76±1.83) were enrolled to the study and divided into 2 groups. Patients with phenotype with FAI<5 were classified as group 1, PCOS patients with FAI>5 formed group 2. All subjects underwent standard meal test. Serum GIP concentration was determined both at fasting and at 60 min of the test. Calculations were carried out using Statistica 10.

Results: Mann-Whitney test indicated a statistically significant difference in medians values of GIP plasma levels between groups on fasting (36.4 pg/ml vs. 59.6 pg/ml; p=0.0007) and at 60 min after meal test (50.1 pg/ml vs. 72.5 pg/ml; p=0.006). Spearman test indicated significant positive correlation between FAI and GIP levels at 0’ and 60’ in total study population (0’:R=0.37;p=0.008; 60’:R=0.28; p=0.049).

Conclusion: Excess androgen activity might be a factor contributing to alter secretion of incretins in lean PCOS women. However it could not be ruled out that it is also possible that increased GIP levels might induce hyperandrogenemia in PCOS. An increased GIP levels may induce hyperinsulinemia and play an additive to insulin resistance role in progression to diabetes mellitus type 2 (DMT2).

• References

• 1 Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157
  CrossrefPubMedGoogle Scholar
• 2 Kieffer TJ, Habener JF. The glucagon-like peptides. Endocrine Reviews 1999; 20: 876-913
  CrossrefPubMedGoogle Scholar
• 3 Christensen M, Vedtofte L, Holst JJ et al. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose dependent regulator of glucagon and insulin secretion in humans. Diabetes 2011; 60: 3103-3109
  CrossrefPubMedGoogle Scholar
• 4 Farilla L, Bulotta A, Hirshberg B et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144: 5149-5158
  CrossrefPubMedGoogle Scholar
• 5 Li Y, Hansotia T, Yusta B et al. Glucagon-like peptide-1 receptor signalingmodulates beta cell apoptosis. J Biol Chem 2003; 278: 471-478
  CrossrefPubMedGoogle Scholar
• 6 Asuncion M, Calvo RM, San Millan JL et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Cau Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 2434-2438
  CrossrefPubMedGoogle Scholar
• 7 Knochenhauer ES, Key TJ, Kahsar-Miller M et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. J Clin Endocrinol Metab 1998; 83: 3078-3082
  CrossrefPubMedGoogle Scholar
• 8 Ehrmann DA, Barnes RB, Rosenfield RL et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22: 141-146
  CrossrefPubMedGoogle Scholar
• 9 Legro RS, Kunselman AR, Dodson WC et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84: 165-169
  CrossrefPubMedGoogle Scholar
• 10 Weerakiet S, Srisombut C, Bunnag P et al. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. Int J Gynaecol Obstet 2001; 75: 177-184
  CrossrefPubMedGoogle Scholar
• 11 Svendsen PF, Nilas L, Madsbad S et al. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. Metabolism 2009; 58: 586-593
  CrossrefPubMedGoogle Scholar
• 12 Miyawaki K, Yamada Y, Ban N et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002; 8: 738-742
  CrossrefPubMedGoogle Scholar
• 13 Vrbikova J, Hill M, Bendlova B et al. Incretin levels in polycystic ovary syndrome. Eur J Endocrinol 2008; 159: 121-127
  CrossrefPubMedGoogle Scholar
• 14 Dupre J, Ross SA, Watson D et al. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973; 37: 826-828
  CrossrefPubMedGoogle Scholar
• 15 Azziz R, Carmina E, Dewailly D et al. The Androgen Exsess and PCOS Society criteria for the polycystic ocary syndrome: the complete task force report. Fertil Steril 2009; 91: 456-488
  CrossrefPubMedGoogle Scholar
• 16 Yildiz BO, Bozdag G, Harmanci A et al. Increased circulating soluble P-selectin in polycystic ovary syndrome. Fertility and Sterility 2010; 93: 2311-2315
  CrossrefPubMedGoogle Scholar
• 17 Yildiz BO, Bolour S, Woods K et al. Visually scoring hirsutism. Hum Reprod Update 2010; 16: 51-64
  Google Scholar
• 18 Aydin K, Arusoglut G, Koksalt G et al. Fasting and post-prandial glucagon like peptide 1 and oral contraception in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2014; 81: 588-592
  CrossrefPubMedGoogle Scholar
• 19 Gama R, Norris F, Wright J et al. The entero-insular axis in polycystic ovarian syndrome. Ann Clin Biochem 1996; 33: 190-195
  CrossrefPubMedGoogle Scholar
• 20 Pontikis C, Yavropoulou MP, Toulis KA et al. The Incretin Effect and Secretion in Obese and Lean Women with Polycystic Ovary Syndrome: A Pilot Study. J Womens Health (Larchmt) 2011; 20: 971-976
  CrossrefPubMedGoogle Scholar
• 21 Goodarzi MO, Carmina E, Azziz R et al. DHEA, DHEAS and PCOS. J Steroid Biochem Mol Biol 2015; 145: 213-25
  CrossrefPubMedGoogle Scholar
• 22 Kassi E, Diamanti-Kandarakis E. The effects of insulin sensitizers on the cardiovascular risk factors in women with polycystic ovary syndrome. J Endocrinol Invest 2008; 31: 1124-1131
  CrossrefPubMedGoogle Scholar
• 23 Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004; 287: 199-206
  CrossrefPubMedGoogle Scholar
• 24 Schou JH, Pilgaard K, Vilsboll T et al. Normal secretion and action of the gut incretin hormones glucagon-like peptide–1 and glucosedependent insulinotropic polypeptide in young men with low birth weight. J Clin Endocrinol Metab 2005; 90: 4912-4919
  CrossrefPubMedGoogle Scholar